Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis

Journal of Human Hypertension volume 33, pages 795–806 (2019)Cite this article

Subjects

A Correction to this article was published on 29 July 2022

This article has been updated

Abstract

The role of the direct renin inhibitor aliskiren in hypertension is not fully established and use of aliskiren in diabetic patients is especially controversial. A systematic review investigating both short-term diastolic and systolic blood pressure (DBP and SBP) reduction and long-term cardiovascular outcomes has not been conducted. Therefore, we aimed to fill this gap by investigating BP reduction, major cardiovascular outcomes, and mortality of aliskiren compared to other antihypertensive therapy. We searched PubMed and Embase databases for relevant randomized controlled trials (RCTs). Using a random-effects model, weighted mean difference (WMD) and relative risk (WRR) with 95% confidence interval (CI) were used to measure the effect of aliskiren therapy in the management of hypertension and major cardiovascular outcomes. Thirty seven RCTs with a total of 35,916 patients were included. Aliskiren induced slightly greater DBP and SBP reductions than other antihypertensive agents (WMD −0.77 mmHg, 95% CI [−2.01;0.46 mmHg] and WMD −1.14 mmHg, 95% CI [−2.78;0.50 mmHg], respectively). Aliskiren did not reduce total mortality or cardiovascular death. In patients with diabetes, aliskiren add-on therapy may have the potential to increase total mortality and cardiovascular death (WRR 1.06, 95% CI [0.88;1.28] and WRR 1.09, 95% CI [0.94;1.24], respectively). Despite superior BP-reducing effect, aliskiren is not recommended as first-line treatment in hypertensive patients as it does not reduce mortality and major cardiovascular outcomes. Dual renin–angiotensin–aldosterone system inhibition with aliskiren should be avoided in diabetic patients, while the use of aliskiren monotherapy remains to be investigated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Change history

References

  1. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control. A systematic analysis of population-based 374 studies from 90 countries. Circulation. 2016;134:441–50.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Authors/Task Force M, Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.

    Article  Google Scholar 

  3. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–8.

    Article  CAS  PubMed  Google Scholar 

  4. Brown MJ. Renin: friend or foe? Heart (Br Card Soc). 2007;93:1026–33.

    Article  CAS  Google Scholar 

  5. Joseph K, Tholanikunnel TE, Kaplan AP. In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme. J Renin Angiotensin Aldosterone Syst. 2015;16:321–7.

    Article  CAS  PubMed  Google Scholar 

  6. White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich, Conn). 2010;12:765–75.

    Article  CAS  Google Scholar 

  7. Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract. 2017;5:744–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Fisher ND, Hollenberg NK. Is there a future for renin inhibitors? Expert Opin Investig Drugs. 2001;10:417–26.

    Article  CAS  PubMed  Google Scholar 

  9. Chen Y, Meng L, Shao H, Yu F. Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis. Hypertens Res. 2012;36:252.

    Article  PubMed  CAS  Google Scholar 

  10. Zhang JT, Chen KP, Guan T, Zhang S. Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials. Drug Des Dev Ther. 2015;9:1963–71.

    CAS  Google Scholar 

  11. Fu S, Wen X, Han F, Long Y, Xu G. Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis. Oncotarget. 2017;8:89364–74.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zheng SL, Roddick AJ, Ayis S. Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: a systematic review and meta-analysis of 13,395 patients. Diabetes Vasc Dis Res. 2017;14:400–6.

    Article  CAS  Google Scholar 

  13. Musini VM, Lawrence KA, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev. 2017;4:Cd007066.

    PubMed  Google Scholar 

  14. Moher D, Liberati A, Tetzlaff J, Altman DG. The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Jadad AR. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  16. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:997–1005.

    Article  CAS  PubMed  Google Scholar 

  17. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–26.

    Article  CAS  PubMed  Google Scholar 

  18. Pool JL, Schmieder RE, Azizi M, Aldigier J-C, Januszewicz A, Zidek W, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan*. Am J Hypertens. 2007;20:11–20.

    Article  CAS  PubMed  Google Scholar 

  19. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157–63.

    Article  CAS  PubMed  Google Scholar 

  20. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet (Lond, Engl). 2007;370:221–9.

    Article  CAS  Google Scholar 

  21. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17–24.

    Article  CAS  PubMed  Google Scholar 

  22. Puig JG, Schunkert H, Taylor AA, Boye S, Jin J, Keefe DL. Evaluation of the dose–response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clin Ther. 2009;31:2839–50.

    Article  CAS  PubMed  Google Scholar 

  23. Villa G, Le Breton S, Ibram G, Keefe DL. Efficacy, safety, and tolerability of aliskiren monotherapy administered with a light meal in elderly hypertensive patients: a randomized, double-blind, placebo-controlled, dose-response evaluation study. J Clin Pharmacol. 2012;52:1901–11.

    Article  CAS  PubMed  Google Scholar 

  24. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009;119:417–25.

    Article  CAS  PubMed  Google Scholar 

  25. Littlejohn TW III, Jones SW, Zhang J, Hsu H, Keefe DL. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. J Hum Hypertens. 2013;27:321–7.

    Article  CAS  PubMed  Google Scholar 

  26. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26:589–99.

    Article  CAS  PubMed  Google Scholar 

  27. Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2008;9:163–75.

    Article  CAS  PubMed  Google Scholar 

  28. Krone W, Hanefeld M, Meyer HF, Jung T, Bartlett M, Yeh CM, et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens. 2011;25:186–95.

    Article  CAS  PubMed  Google Scholar 

  29. Zhu JR, Sun NL, Yang K, Hu J, Xu G, Hong H, et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertens Res. 2012;35:28–33.

    Article  CAS  PubMed  Google Scholar 

  30. Verdecchia P, Calvo C, Mockel V, Keeling L, Satlin A. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press. 2007;16:381–91.

    Article  CAS  PubMed  Google Scholar 

  31. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (Dallas, Tex: 1979). 2007;49:1047–55.

    Article  CAS  Google Scholar 

  32. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190–8.

    Article  CAS  PubMed  Google Scholar 

  33. Blumenstein M, Romaszko J, Calderon A, Andersen K, Ibram G, Liu Z, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin. 2009;25:903–10.

    Article  CAS  PubMed  Google Scholar 

  34. Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens (Greenwich, Conn). 2009;11:324–32.

    Article  CAS  Google Scholar 

  35. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. 2010;24:600–8.

    Article  CAS  PubMed  Google Scholar 

  36. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet (Lond, Engl). 2011;377:312–20.

    Article  CAS  Google Scholar 

  37. Basile J, Babazadeh S, Lillestol M, Botha J, Yurkovic C, Weitzman R. Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study. J Clin Hypertens (Greenwich, Conn). 2011;13:162–9.

    Article  CAS  Google Scholar 

  38. Black HR, Weinberger MH, Purkayastha D, Lee J, Sridharan K, Israel M, et al. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. J Clin Hypertens (Greenwich, Conn). 2011;13:571–81.

    Article  CAS  Google Scholar 

  39. Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. Am J Cardiovasc Drugs. 2011;11:327–33.

    Article  CAS  PubMed  Google Scholar 

  40. Pfeiffer D, Rennie N, Papst CC, Zhang J. Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy yen. Curr Vasc Pharmacol. 2012;10:773–80.

    Article  CAS  PubMed  Google Scholar 

  41. Flack JM, Yadao AM, Purkayastha D, Samuel R, White WB. Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension. J Am Soc Hypertens. 2012;6:142–51.

    Article  CAS  PubMed  Google Scholar 

  42. Lacourciere Y, Taddei S, Konis G, Fang H, Severin T, Zhang J. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. J Hypertens. 2012;30:2047–55.

    Article  CAS  PubMed  Google Scholar 

  43. Braun-Dullaeus RC, Shustov SB, Alvarez C, Rogelio GG, Zhang J, Hristoskova S, et al. Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial. Int J Clin Pract. 2012;66:834–42.

    Article  CAS  PubMed  Google Scholar 

  44. Teo KK, Pfeffer M, Mancia G, O’Donnell M, Dagenais G, Diaz R, et al. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. Eur Heart J. 2014;35:1743–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Imbalzano E, Scarpelli M, Mandraffino G, Creazzo M, Lizio G, Trapani G, et al. Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. J Renin Angiotensin Aldosterone Syst. 2015;16:956–64.

    Article  CAS  PubMed  Google Scholar 

  46. Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJM, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010;31:1993–2005.

    Article  CAS  PubMed  Google Scholar 

  47. Solomon SD, Hee Shin S, Shah A, Skali H, Desai A, Kober L, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32:1227–34.

    Article  CAS  PubMed  Google Scholar 

  48. Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.

    Article  CAS  PubMed  Google Scholar 

  49. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309:1125–35.

    Article  CAS  PubMed  Google Scholar 

  50. Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, et al. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013;310:1135–44.

    Article  CAS  PubMed  Google Scholar 

  51. McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016;374:1521–32.

    Article  CAS  PubMed  Google Scholar 

  52. Shah Amil M, Shin Sung H, Takeuchi M, Skali H, Desai Akshay S, Køber L, et al. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail. 2014;14:185–92.

    Article  CAS  Google Scholar 

  53. Maggioni AP, Greene SJ, Fonarow GC, Böhm M, Zannad F, Solomon SD, et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J. 2013;34:3117–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Kristensen Søren L, Mogensen Ulrik M, Tarnesby G, Gimpelewicz Claudio R, Ali Mohammed A, Shao Q, et al. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. Eur J Heart Fail. 2017;20:136–47.

    Article  PubMed  CAS  Google Scholar 

  55. Seliger SL, Fried LF. Serum potassium in dual renin–angiotensin–aldosterone system blockade. Clin J Am Soc Nephrol. 2014;9:219–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, et al. The effect of combination treatment with aliskiren and blockers of the renin–angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46.

    Article  CAS  PubMed  Google Scholar 

  58. Puri R, Nissen SE, Menon V, Shao M, Hsu A, Bakris GL, et al. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015;243:553–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Henrik L Bjerre, Julie B Christensen.

Authors and Affiliations

  1. Department of Biomedicine, Pharmacology, Aarhus University, Aarhus C, Denmark

    Henrik Laurits Bjerre, Julie B Christensen, Niels Henrik Buus, Ulf Simonsen & Junjing Su

  2. Department of Renal Medicine, Aarhus University Hospital, Aarhus C, Denmark

    Niels Henrik Buus

Authors
  1. Henrik Laurits Bjerre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julie B Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Niels Henrik Buus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ulf Simonsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junjing Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junjing Su.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: Due to an error in an author name.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bjerre, H.L., Christensen, J.B., Buus, N.H. et al. The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis. J Hum Hypertens 33, 795–806 (2019). https://doi.org/10.1038/s41371-018-0149-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-018-0149-8

Search

Advanced search

Quick links